Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mesalamine 2 g extended release granules for maintenance of remission in ulcerative colitis
2015-002558-11Phase 3Completed
- Sponsor
- Ferring International PharmaScience Center U.S., Inc.
- Start
- Nov 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in autoimmune colitis comparing Mesalamine 2 g extended release granules once daily with Placebo once daily (2 arms). Primary endpoint: Remission at end of maintenance period. Started Nov 2015; status: completed.
02
Drugs
Salcrozine
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2015-002558-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002558-11.